{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:56:57Z","timestamp":1776495417005,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s10096-023-04701-x","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T04:09:17Z","timestamp":1699848557000},"page":"177-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients"],"prefix":"10.1007","volume":"43","author":[{"given":"Matthijs","family":"Oyaert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Ang\u00e9lique","family":"De Scheerder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Van Herrewege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Laureys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Van Assche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Cambron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Naesens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levi","family":"Hoste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karlien","family":"Claes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomeen","family":"Haerynck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa","family":"Kerre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Van Laecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizaveta","family":"Padalko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"4701_CR1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE et al (2020) Factors associated with COVID19 related death using Opensafely. Nature 584:430\u2013436","journal-title":"Nature"},{"key":"4701_CR2","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1016\/S2352-3018(21)00239-3","volume":"8","author":"X Yang","year":"2021","unstructured":"Yang X, Sun J, Patel RC, Zhang J, Guo S, Zheng Q et al (2021) Associations between HIV infection and clinical spectrum of COVID19: a population level analysis based on US National COVID cohort collaborations (NC3) data. Lancet HIV 8:e690-700","journal-title":"Lancet HIV"},{"key":"4701_CR3","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.3201\/eid2708.211145","volume":"27","author":"T Schwartz","year":"2021","unstructured":"Schwartz T, Tober-Lau P, Hillus D, Helbig ET, Lippert LJ, Thibeault C et al (2021) Delayed antibody and T-cell response to BNT162b2 vaccination in the elderly, Germany. Emerg Infect Dis 27:2174\u20132178","journal-title":"Emerg Infect Dis"},{"key":"4701_CR4","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1681\/ASN.2021040490","volume":"32","author":"C Danthu","year":"2021","unstructured":"Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M et al (2021) Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol 32:2153\u20132158","journal-title":"J Am Soc Nephrol"},{"key":"4701_CR5","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","volume":"80","author":"UM Geisen","year":"2021","unstructured":"Geisen UM, Berner DK, Tran F, S\u00fcmb\u00fcl M, Vullriede L, Ciripoi M et al (2021) Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 80:1306\u20131311","journal-title":"Ann Rheum Dis"},{"key":"4701_CR6","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1093\/ckj\/sfac174","volume":"15","author":"C Cantarelli","year":"2022","unstructured":"Cantarelli C, Angeletti A, Perin L, Russo LS, Sabiu G, Podest\u00e0 MA et al (2022) Immune responses to SARS-CoV-2 in dialysis and kidney transplantation. Clin Kidney J 15:1816\u20131828","journal-title":"Clin Kidney J"},{"key":"4701_CR7","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/tri.14029","volume":"34","author":"M Giannella","year":"2021","unstructured":"Giannella M, Pierrotti LC, Helanter\u00e4 I, Manuel O (2021) SARS-CoV-2 vaccination in solid-organ transplant recipients: what the clinician needs to know. Transpl Int 34:1776\u20131788","journal-title":"Transpl Int"},{"key":"4701_CR8","doi-asserted-by":"publisher","first-page":"988304","DOI":"10.3389\/fimmu.2022.988304","volume":"13","author":"S Zou","year":"2022","unstructured":"Zou S, Guo W, Wu S, Ming F, Tan Y, Wu M et al (2022) Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV. Front Immunol 13:988304","journal-title":"Front Immunol"},{"key":"4701_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00415-022-11353-y","volume":"270","author":"P Nicolas","year":"2023","unstructured":"Nicolas P, Marion-Moffet H, Gossez M, Vukusic S, Monneret G, Marignier R et al (2023) Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies. J Neurol 270:32\u201336","journal-title":"J Neurol"},{"key":"4701_CR10","doi-asserted-by":"publisher","first-page":"901055","DOI":"10.3389\/fimmu.2022.901055","volume":"13","author":"D Mauro","year":"2022","unstructured":"Mauro D, Ciancio A, Di Vico C, Passariello L, Rozza G, Pasuale MD et al (2022) Serological response to BNT162b2 anti-SARS-CoV-2 vaccination in patients with inflammatory rheumatic diseases: results from the RHEUVAX cohort. Front Immunol 13:901055","journal-title":"Front Immunol"},{"key":"4701_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10875-022-01382-7","volume":"43","author":"L Erra","year":"2023","unstructured":"Erra L, Uriarte I, Colado A, Paolini MV, Seminario G, Fernandez JB et al (2023) COVID-19 vaccination responses with different vaccine platforms in patients with inborn errors of immunity. J Clin Immunol 43:271\u2013285","journal-title":"J Clin Immunol"},{"key":"4701_CR12","unstructured":"Food and Drug Administration (2023).\u00a0\u00a0https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-second-booster-dose-two-covid-19-vaccines-older-and [Accessed February 25, 2023]"},{"key":"4701_CR13","unstructured":"Health Belgium (2022).\u00a0\u00a0https:\/\/www.health.belgium.be\/sites\/default\/files\/uploads\/fields\/fpshealth_theme_file\/20220303_hgr-9691_booster_immunogecompromitteerden_vweb.pdf [Accessed February 21, 2023]"},{"key":"4701_CR14","unstructured":"WHO (2020) Working Group on the Clinical Characterisation and Management of COVID-19 Infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 8:e192-e197"},{"key":"4701_CR15","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jinf.2022.09.006","volume":"85","author":"ME Moussaoui","year":"2022","unstructured":"Moussaoui ME, Desmecht S, Tashkeev A, Lambert N, Maes N, Braghini J et al (2022) Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-na\u00efve people living with HIV. J Infect 85:702\u2013709","journal-title":"J Infect"},{"key":"4701_CR16","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1016\/S2214-109X(21)00593-3","volume":"10","author":"EW Parker","year":"2022","unstructured":"Parker EW, Desai S, Marti M, Nohynek H, Kaslow DC, Kochhar S et al (2022) Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review. Lancet Glob Health 10:e326\u2013e328","journal-title":"Lancet Glob Health"},{"key":"4701_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.ekir.2022.02.007","volume":"7","author":"AS De Vriese","year":"2022","unstructured":"De Vriese AS, Van Praet J, Reynders M, Heylen L, Viaene L, Caluw\u00e9 R et al (2022) Longevity and clinical effectiveness of the humoral and cellular responses to SARS-CoV-2 vaccination in hemodialysis patients. Kidney Int Rep 7:1103\u20131107","journal-title":"Kidney Int Rep"},{"key":"4701_CR18","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1681\/ASN.2021070966","volume":"32","author":"E Schrezenmeier","year":"2021","unstructured":"Schrezenmeier E, Rincon-Arevalo H, Stefanski AL, Potekhin A, Staub-Hohenbleicher H, Choi M et al (2021) B and T cell responses after a third dose of SARS-CoV-2 vaccine in kidney transplant patients. J Am Soc Nephrol 32:3027\u20133033","journal-title":"J Am Soc Nephrol"},{"key":"4701_CR19","doi-asserted-by":"publisher","first-page":"e1178","DOI":"10.1212\/NXI.0000000000001178","volume":"9","author":"V Palomares Cabeza","year":"2022","unstructured":"Palomares Cabeza V, Kummer LYL, Wieske L, Hagen RR, Duurland M, Konijn VAL et al (2022) Longitudinal T-cell responses after a third SARS-CoV-2 vaccination in patients with multiple sclerosis on ocrelizumab or fingolimod. Neurol Neuroimmunol Neuroinflamm 9:e1178","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4701_CR20","doi-asserted-by":"crossref","first-page":"e1187","DOI":"10.1016\/S2665-9913(21)00394-5","volume":"4","author":"I Jyssum","year":"2022","unstructured":"Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J et al (2022) Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol 4:e1187","journal-title":"Lancet Rheumatol"},{"key":"4701_CR21","doi-asserted-by":"publisher","first-page":"858399","DOI":"10.3389\/fimmu.2022.858399","volume":"13","author":"M Oyaert","year":"2022","unstructured":"Oyaert M, De Scheerder MA, Van Herreweghe S, Laureys G, Van Assche S, Cambron M et al (2022) Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients. Front Immunol 13:858399","journal-title":"Front Immunol"},{"key":"4701_CR22","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1016\/S2666-5247(22)00036-2","volume":"3","author":"L Guo","year":"2022","unstructured":"Guo L, Wang G, Wang Y, Zhang Q, Ren L, Gu X et al (2022) SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe 3:e348\u2013e356","journal-title":"Lancet Microbe"},{"key":"4701_CR23","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","volume":"27","author":"EM Bange","year":"2021","unstructured":"Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J et al (2021) CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med 27:1280\u20131289","journal-title":"Nat Med"},{"key":"4701_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A et al (2020) Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183:158\u201368.e14","journal-title":"Cell"},{"key":"4701_CR25","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.cell.2020.10.001","volume":"183","author":"BJ Meckiff","year":"2020","unstructured":"Meckiff BJ, Ram\u00edrez-Su\u00e1stegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H et al (2020) Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19. Cell 183:1340\u201353.e16","journal-title":"Cell"},{"key":"4701_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jneuroim.2019.04.017","volume":"332","author":"AE Lovett-Racke","year":"2019","unstructured":"Lovett-Racke AE, Gormley M, Liu Y, Yang Y, Graham C, Wray S et al (2019) B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol 332:187\u2013197","journal-title":"J Neuroimmunol"},{"key":"4701_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00415-021-10663-x","volume":"269","author":"S Guerrieri","year":"2022","unstructured":"Guerrieri S, Lazzarin S, Zanetta C, Nozzolillo A, Filippi M, Moiola L (2022) Serological response to SARSCoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real life experience. J Neurol 269:39\u201343","journal-title":"J Neurol"},{"key":"4701_CR28","doi-asserted-by":"publisher","first-page":"103413","DOI":"10.1016\/j.msard.2021.103413","volume":"57","author":"WL Conte","year":"2022","unstructured":"Conte WL (2022) B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: a case-control study. Mult Scler Relat Disord 57:103413","journal-title":"Mult Scler Relat Disord"},{"key":"4701_CR29","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1001\/jamaneurol.2021.3599","volume":"78","author":"L Brill","year":"2021","unstructured":"Brill L, Rechtman A, Zveik O, Haham N, Oiknine-Djian E, Wolf DG et al (2021) Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol 78:1510\u20131514","journal-title":"JAMA Neurol"},{"key":"4701_CR30","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1007\/s10072-021-05397-7","volume":"42","author":"A Gallo","year":"2021","unstructured":"Gallo A, Capuano R, Donnarumma G, Bisecco A, Grimaldi E, Conte M et al (2021) Preliminary evidence of blunted humoral response to SARSCoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab. Neurol Sci 42:3523\u20133526","journal-title":"Neurol Sci"},{"key":"4701_CR31","doi-asserted-by":"publisher","first-page":"103581","DOI":"10.1016\/j.ebiom.2021.103581","volume":"72","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, Inglese M, Schiavetti I, Carmiscianno L, Laroni A, Lapucci C et al (2021) Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine 72:103581","journal-title":"EBioMedicine"},{"key":"4701_CR32","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1111\/bcp.14658","volume":"87","author":"E Gibiansky","year":"2021","unstructured":"Gibiansky E, Petry C, Mercier F, G\u00fcnther A, Herman A, Kappos L et al (2021) Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol 87:2511\u20132520","journal-title":"Br J Clin Pharmacol"},{"key":"4701_CR33","doi-asserted-by":"publisher","first-page":"104765","DOI":"10.1016\/j.jcv.2021.104765","volume":"136","author":"J Van Elslande","year":"2021","unstructured":"Van Elslande J, Oyaert M, Ailliet S, Van Ranst M, Lorent N, Vande Weygaerde Y et al (2021) Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection. J Clin Virol 136:104765","journal-title":"J Clin Virol"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-023-04701-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T21:45:39Z","timestamp":1730497539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-023-04701-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["4701"],"URL":"https:\/\/doi.org\/10.1007\/s10096-023-04701-x","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"4 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective study was performed at the Ghent University Hospital after approval by the Ghent University ethics committee (B6702021000426).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Prior to inclusion in the study, all participants signed informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}